FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366976302> ?p ?o ?g. }

• W4366976302 endingPage "538" @default.
• W4366976302 startingPage "530" @default.
• W4366976302 abstract "The aim of this study was to summarize the current preclinical and clinical evidence on the association between exposure to gadolinium (Gd) compounds and skin toxicity in a setting similar to clinical practice.A search of MEDLINE and PubMed references from January 2000 to December 2022 was performed using keywords related to gadolinium deposition and its effects on the skin, such as gadolinium, gadolinium-based contrast agents, skin, deposition, and toxicity. In addition, cross-referencing was added when appropriate. For preclinical in vitro studies, we included all the studies that analyzed the response of human dermal fibroblasts to exposure to various gadolinium compounds. For preclinical animal studies and clinical studies, we included only those that analyzed animals or patients with preserved renal function (estimated glomerular filtration rate >30 mL/min/1.73 m 2 ), using a dosage of gadolinium-based contrast agents (GBCAs) similar to that commonly applied (0.1 mmol/kg).Forty studies were selected. Preclinical findings suggest that Gd compounds can produce profibrotic responses in the skin in vitro, through the activation and proliferation of dermal fibroblasts and promoting their myofibroblast differentiation. Gadolinium influences the process of collagen production and the collagen content of skin, by increasing the levels of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1. Preclinical animal studies show that Gd can deposit in the skin with higher concentrations when linear GBCAs are applied. However, these deposits decrease over time and are not associated with obvious macroscopic or histological modifications. The clinical relevance of GBCAs in inducing small fiber neuropathy remains to be determined. Clinical studies show that Gd is detectable in the skin and hair of subjects with normal renal function in higher concentrations after intravenous administration of linear compared with macrocyclic GBCA. However, these deposits decrease over time and are not associated with cutaneous or histological modifications. Also, subclinical dermal involvement related to linear GBCA exposure may be detectable on brain MRI. There is no conclusive evidence to support a causal relationship between GBCA administration at the clinical dose and cutaneous manifestations in patients with normal renal function.Gadolinium can produce profibrotic responses in the skin, especially acting on fibroblasts, as shown by preclinical in vitro studies. Gadolinium deposits are detectable in the skin even in subjects with normal renal function with higher concentrations when linear GBCAs are used, as confirmed by both preclinical animal and human studies. There is no proof to date of a cause-effect relationship between GBCA administration at clinical doses and cutaneous consequences in patients with normal renal function. Multiple factors, yet to be determined, should be considered for sporadic patients with normal renal function who develop clinical skin manifestations temporally related to GBCA administration." @default.
• W4366976302 created "2023-04-27" @default.
• W4366976302 creator A5008853887 @default.
• W4366976302 creator A5022564566 @default.
• W4366976302 creator A5022902115 @default.
• W4366976302 creator A5028587946 @default.
• W4366976302 creator A5031009054 @default.
• W4366976302 creator A5048556415 @default.
• W4366976302 creator A5058339426 @default.
• W4366976302 creator A5058652761 @default.
• W4366976302 creator A5063275381 @default.
• W4366976302 creator A5064880182 @default.
• W4366976302 creator A5070504139 @default.
• W4366976302 creator A5075702721 @default.
• W4366976302 creator A5084473005 @default.
• W4366976302 creator A5087480086 @default.
• W4366976302 date "2023-04-22" @default.
• W4366976302 modified "2023-10-18" @default.
• W4366976302 title "Skin Toxicity After Exposure to Gadolinium-Based Contrast Agents in Normal Renal Function, Using Clinical Approved Doses" @default.
• W4366976302 cites W1965786357 @default.
• W4366976302 cites W1976690287 @default.
• W4366976302 cites W1980682003 @default.
• W4366976302 cites W1983021880 @default.
• W4366976302 cites W2037832318 @default.
• W4366976302 cites W2039220271 @default.
• W4366976302 cites W2043029363 @default.
• W4366976302 cites W2061948232 @default.
• W4366976302 cites W2062162151 @default.
• W4366976302 cites W2081024612 @default.
• W4366976302 cites W2081547421 @default.
• W4366976302 cites W2091470298 @default.
• W4366976302 cites W2108281282 @default.
• W4366976302 cites W2108452679 @default.
• W4366976302 cites W2109768646 @default.
• W4366976302 cites W2133793934 @default.
• W4366976302 cites W2136903044 @default.
• W4366976302 cites W2145961680 @default.
• W4366976302 cites W2312938814 @default.
• W4366976302 cites W2315022551 @default.
• W4366976302 cites W2318486690 @default.
• W4366976302 cites W2407825305 @default.
• W4366976302 cites W2425960137 @default.
• W4366976302 cites W2507120718 @default.
• W4366976302 cites W2515055839 @default.
• W4366976302 cites W2572332131 @default.
• W4366976302 cites W2737069440 @default.
• W4366976302 cites W2763313954 @default.
• W4366976302 cites W2775884912 @default.
• W4366976302 cites W2899393623 @default.
• W4366976302 cites W2906883880 @default.
• W4366976302 cites W2994207972 @default.
• W4366976302 cites W3010851348 @default.
• W4366976302 cites W3014817886 @default.
• W4366976302 cites W3016593844 @default.
• W4366976302 cites W3022131483 @default.
• W4366976302 cites W3028319859 @default.
• W4366976302 cites W3039030012 @default.
• W4366976302 cites W3070754678 @default.
• W4366976302 cites W3163115409 @default.
• W4366976302 cites W3168894130 @default.
• W4366976302 cites W3185223421 @default.
• W4366976302 cites W3201349215 @default.
• W4366976302 cites W3212095163 @default.
• W4366976302 cites W4205842590 @default.
• W4366976302 cites W4226210707 @default.
• W4366976302 cites W4231308019 @default.
• W4366976302 cites W4242230604 @default.
• W4366976302 cites W4282977248 @default.
• W4366976302 cites W4318932564 @default.
• W4366976302 doi "https://doi.org/10.1097/rli.0000000000000973" @default.
• W4366976302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37185158" @default.
• W4366976302 hasPublicationYear "2023" @default.
• W4366976302 type Work @default.
• W4366976302 citedByCount "2" @default.
• W4366976302 countsByYear W43669763022023 @default.
• W4366976302 crossrefType "journal-article" @default.
• W4366976302 hasAuthorship W4366976302A5008853887 @default.
• W4366976302 hasAuthorship W4366976302A5022564566 @default.
• W4366976302 hasAuthorship W4366976302A5022902115 @default.
• W4366976302 hasAuthorship W4366976302A5028587946 @default.
• W4366976302 hasAuthorship W4366976302A5031009054 @default.
• W4366976302 hasAuthorship W4366976302A5048556415 @default.
• W4366976302 hasAuthorship W4366976302A5058339426 @default.
• W4366976302 hasAuthorship W4366976302A5058652761 @default.
• W4366976302 hasAuthorship W4366976302A5063275381 @default.
• W4366976302 hasAuthorship W4366976302A5064880182 @default.
• W4366976302 hasAuthorship W4366976302A5070504139 @default.
• W4366976302 hasAuthorship W4366976302A5075702721 @default.
• W4366976302 hasAuthorship W4366976302A5084473005 @default.
• W4366976302 hasAuthorship W4366976302A5087480086 @default.
• W4366976302 hasConcept C126322002 @default.
• W4366976302 hasConcept C142724271 @default.
• W4366976302 hasConcept C159641895 @default.
• W4366976302 hasConcept C172268261 @default.
• W4366976302 hasConcept C178790620 @default.
• W4366976302 hasConcept C185592680 @default.
• W4366976302 hasConcept C2778653478 @default.
• W4366976302 hasConcept C2781027423 @default.

• next